JP2016535758A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535758A5
JP2016535758A5 JP2016534884A JP2016534884A JP2016535758A5 JP 2016535758 A5 JP2016535758 A5 JP 2016535758A5 JP 2016534884 A JP2016534884 A JP 2016534884A JP 2016534884 A JP2016534884 A JP 2016534884A JP 2016535758 A5 JP2016535758 A5 JP 2016535758A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
conh
haloalkyl
con
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016534884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535758A (ja
JP6458270B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/051459 external-priority patent/WO2015024010A2/en
Publication of JP2016535758A publication Critical patent/JP2016535758A/ja
Publication of JP2016535758A5 publication Critical patent/JP2016535758A5/ja
Application granted granted Critical
Publication of JP6458270B2 publication Critical patent/JP6458270B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016534884A 2013-08-16 2014-08-18 置換されたヒドロキサム酸化合物 Expired - Fee Related JP6458270B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361866823P 2013-08-16 2013-08-16
US61/866,823 2013-08-16
US201361867933P 2013-08-20 2013-08-20
US61/867,933 2013-08-20
PCT/US2014/051459 WO2015024010A2 (en) 2013-08-16 2014-08-18 Substituted hydroxamic acid compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018224004A Division JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Publications (3)

Publication Number Publication Date
JP2016535758A JP2016535758A (ja) 2016-11-17
JP2016535758A5 true JP2016535758A5 (enExample) 2017-09-28
JP6458270B2 JP6458270B2 (ja) 2019-01-30

Family

ID=52468825

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534884A Expired - Fee Related JP6458270B2 (ja) 2013-08-16 2014-08-18 置換されたヒドロキサム酸化合物
JP2018224004A Pending JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018224004A Pending JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Country Status (6)

Country Link
US (1) US10647664B2 (enExample)
EP (1) EP3041354A4 (enExample)
JP (2) JP6458270B2 (enExample)
AU (1) AU2014306451B2 (enExample)
CA (1) CA2921427A1 (enExample)
WO (1) WO2015024010A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015024010A2 (en) * 2013-08-16 2015-02-19 Duke University Substituted hydroxamic acid compounds
US9796686B2 (en) 2014-05-16 2017-10-24 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3H)-one derivatives
ES2909122T3 (es) 2015-11-09 2022-05-05 Forge Therapeutics Inc Compuestos a base de hidroxipiridinona e hidroxipirimidinona para el tratamiento de infecciones bacterianas
EP3374355A4 (en) 2015-11-09 2019-04-17 Forge Therapeutics, Inc. COMPOUNDS BASED ON PYRONE AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
US11034649B2 (en) 2016-04-25 2021-06-15 Duke University Benzoylglycine derivatives and methods of making and using same
CN110072844B (zh) 2016-12-23 2023-06-02 英特维特国际股份有限公司 用于治疗溶血曼海姆菌或睡眠嗜组织菌感染的化合物
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
SG11202007665RA (en) * 2018-02-10 2020-09-29 Kbp Biosciences Co Ltd Compound acting as antibiotics
CA3113226A1 (en) * 2018-09-20 2020-03-26 Forge Therapeutics, Inc. Antibacterial compounds
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
DK4210700T3 (da) 2020-09-09 2025-09-08 Crinetics Pharmaceuticals Inc Formuleringer af en somatostatinmodulator
WO2023055686A1 (en) 2021-09-28 2023-04-06 Blacksmith Medicines, Inc. Lpxc inhibitors and uses thereof
WO2024077160A2 (en) * 2022-10-05 2024-04-11 Duke University Compositions comprising prodrugs of hydroxyamate-based compounds and methods of making and using same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JP2000344752A (ja) * 1999-04-01 2000-12-12 Sumitomo Pharmaceut Co Ltd 点眼剤
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
PL207295B1 (pl) * 2002-01-29 2010-11-30 Serono Lab Podstawione pochodne metylenoamidowe , ich zastosowanie i sposób ich wytwarzania oraz kompozycja farmaceutyczna
BR0309671A (pt) 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
KR101011373B1 (ko) 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 n-히드록시아미드 유도체
ES2552247T3 (es) * 2003-01-08 2015-11-26 The University Of Washington Agentes antibacterianos
US20050154022A1 (en) 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
AT502219B1 (de) 2005-08-04 2007-04-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von 5-substituierten tetrazolen
EP1957449A1 (en) 2005-12-01 2008-08-20 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
CN101528711A (zh) 2006-08-31 2009-09-09 先灵公司 可用作抗细菌剂的乙内酰脲衍生物
WO2008105515A1 (ja) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体
CN101765585B (zh) 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
JP2011525927A (ja) 2008-06-25 2011-09-29 シェーリング コーポレイション 複素環式抗菌剤の合成および使用
CA2732045A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−n−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) * 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011005355A1 (en) 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
CA2774250C (en) 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
SI2512474T1 (sl) 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
SMT201900482T1 (it) * 2010-04-20 2019-09-09 Fujifilm Toyama Chemical Co Ltd Derivato dell'acido idrossammico
US9738604B2 (en) * 2010-09-03 2017-08-22 Duke University Ethynylbenzene derivatives
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
JP6006609B2 (ja) * 2011-10-19 2016-10-12 大正製薬株式会社 新規なヒドロキサム酸誘導体を含有する医薬
WO2013170165A1 (en) * 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
SI2975022T1 (sl) * 2013-03-15 2019-08-30 Fujifilm Toyama Chemical Co., Ltd. Novi derivati hidroksamske kisline ali soli le-teh
WO2015024010A2 (en) * 2013-08-16 2015-02-19 Duke University Substituted hydroxamic acid compounds

Similar Documents

Publication Publication Date Title
JP2016535758A5 (enExample)
JP2012502946A5 (enExample)
JP2020502047A5 (enExample)
JP2019506430A5 (enExample)
JP2016505619A5 (enExample)
JP2017526636A5 (enExample)
JP2013542937A5 (enExample)
JP2007523155A5 (enExample)
JP2016525122A5 (enExample)
JP2007502804A5 (enExample)
JP2010540525A5 (enExample)
JP2013510884A5 (enExample)
JP2007525516A5 (enExample)
JP2009524611A5 (ja) S1p1受容体アゴニスト、免疫抑制剤および抗炎症剤としての3,5ージ(アリールまたはヘテロアリール)イソキサゾールおよび1,2,4−オキサジアゾール
HRP20150049T1 (hr) Derivati oksazolil-metiletera kao agonisti alx-receptora
JP2008505874A5 (enExample)
JP2013500314A5 (enExample)
CA2601508A1 (en) Cyclopropanecarboxamide derivatives
IL273000B2 (en) Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)
JP2013526494A5 (enExample)
JP2017505293A5 (enExample)
JP2013542992A5 (enExample)
JP2014500330A5 (enExample)
JP2017508795A5 (enExample)
JP2019530674A5 (enExample)